Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy

Recent unprecedented advances in treatment for spinal muscular atrophy (SMA) enabled patients to access the first approved disease modifying therapy for the condition. There are however many uncertainties, regarding timing of treatment initiation, response to intervention, treatment effects and long...

Descrición completa

Detalles Bibliográficos

Principais autores:	Didu S. T. Kariyawasam, Arlene D'Silva, Cindy Lin, Monique M. Ryan, Michelle A. Farrar
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2019-08-01
Series:	Frontiers in Neurology
Assuntos:	biomarker spinal muscular atrophy motor unit number estimation compound muscle action potential SMN2 neurofilament
Acceso en liña:	https://www.frontiersin.org/article/10.3389/fneur.2019.00898/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!